ID   PGH2_RAT                Reviewed;         604 AA.
AC   P35355; Q64379; Q925V4;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   02-OCT-2024, entry version 205.
DE   RecName: Full=Prostaglandin G/H synthase 2;
DE            EC=1.14.99.1;
DE   AltName: Full=Cyclooxygenase-2;
DE            Short=COX-2;
DE   AltName: Full=PHS II;
DE   AltName: Full=Prostaglandin H2 synthase 2;
DE            Short=PGH synthase 2;
DE            Short=PGHS-2;
DE   AltName: Full=Prostaglandin-endoperoxide synthase 2;
DE   Flags: Precursor;
GN   Name=Ptgs2; Synonyms=Cox-2, Cox2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7916614; DOI=10.1006/bbrc.1993.2506;
RA   Kennedy B.P., Chan C.C., Culp S.A., Cromlish W.A.;
RT   "Cloning and expression of rat prostaglandin endoperoxide synthase
RT   (cyclooxygenase)-2 cDNA.";
RL   Biochem. Biophys. Res. Commun. 197:494-500(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8352945; DOI=10.1016/0896-6273(93)90192-t;
RA   Yamagata K., Andreasson K.I., Kaufmann W.E., Barnes C.A., Worley P.F.;
RT   "Expression of a mitogen-inducible cyclooxygenase in brain neurons:
RT   regulation by synaptic activity and glucocorticoids.";
RL   Neuron 11:371-386(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Wistar; TISSUE=Intestine;
RX   PubMed=8203528; DOI=10.1152/ajpgi.1994.266.5.g822;
RA   Dubois R.N., Tsujii M., Bishop P., Awad J.A., Makita K., Lanahan A.;
RT   "Cloning and characterization of a growth factor-inducible cyclooxygenase
RT   gene from rat intestinal epithelial cells.";
RL   Am. J. Physiol. 266:G822-G827(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Fischer 344;
RX   PubMed=8274023; DOI=10.1006/abbi.1993.1601;
RA   Feng L., Sun W., Xia Y., Tang W.W., Chanmugam P., Soyoola E., Wilson C.B.,
RA   Hwang D.;
RT   "Cloning two isoforms of rat cyclooxygenase: differential regulation of
RT   their expression.";
RL   Arch. Biochem. Biophys. 307:361-368(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=10816563; DOI=10.1074/jbc.m001611200;
RA   Xu K., Robida A.M., Murphy T.J.;
RT   "Immediate-early MEK-1-dependent stabilization of rat smooth muscle cell
RT   cyclooxygenase-2 mRNA by Galpha(q)-coupled receptor signaling.";
RL   J. Biol. Chem. 275:23012-23019(2000).
RN   [6]
RP   PROTEIN SEQUENCE OF 18-43.
RX   PubMed=1556140; DOI=10.1016/s0021-9258(18)42706-8;
RA   Sirois J., Richards J.S.;
RT   "Purification and characterization of a novel, distinct isoform of
RT   prostaglandin endoperoxide synthase induced by human chorionic gonadotropin
RT   in granulosa cells of rat preovulatory follicles.";
RL   J. Biol. Chem. 267:6382-6388(1992).
RN   [7]
RP   REVIEW ON FUNCTION; TISSUE SPECIFICITY AND INHIBITION BY NSAIDS.
RX   PubMed=10966456; DOI=10.1146/annurev.biochem.69.1.145;
RA   Smith W.L., DeWitt D.L., Garavito R.M.;
RT   "Cyclooxygenases: structural, cellular, and molecular biology.";
RL   Annu. Rev. Biochem. 69:145-182(2000).
RN   [8]
RP   REVIEW ON FUNCTION; INHIBITION BY ASPIRIN AND INVOLVEMENT IN COLORECTAL
RP   CANCER.
RX   PubMed=24605250; DOI=10.4292/wjgpt.v5.i1.40;
RA   Sostres C., Gargallo C.J., Lanas A.;
RT   "Aspirin, cyclooxygenase inhibition and colorectal cancer.";
RL   World J. Gastrointest. Pharmacol. Ther. 5:40-49(2014).
CC   -!- FUNCTION: Dual cyclooxygenase and peroxidase in the biosynthesis
CC       pathway of prostanoids, a class of C20 oxylipins mainly derived from
CC       arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with
CC       a particular role in the inflammatory response. The cyclooxygenase
CC       activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2
CC       (PGG2), and the peroxidase activity reduces PGG2 to the hydroxy
CC       endoperoxide prostaglandin H2 (PGH2), the precursor of all 2-series
CC       prostaglandins and thromboxanes. This complex transformation is
CC       initiated by abstraction of hydrogen at carbon 13 (with S-
CC       stereochemistry), followed by insertion of molecular O2 to form the
CC       endoperoxide bridge between carbon 9 and 11 that defines
CC       prostaglandins. The insertion of a second molecule of O2 (bis-oxygenase
CC       activity) yields a hydroperoxy group in PGG2 that is then reduced to
CC       PGH2 by two electrons. Similarly catalyzes successive cyclooxygenation
CC       and peroxidation of dihomo-gamma-linoleate (DGLA, C20:3(n-6)) and
CC       eicosapentaenoate (EPA, C20:5(n-3)) to corresponding PGH1 and PGH3, the
CC       precursors of 1- and 3-series prostaglandins. In an alternative pathway
CC       of prostanoid biosynthesis, converts 2-arachidonoyl lysophopholipids to
CC       prostanoid lysophopholipids, which are then hydrolyzed by intracellular
CC       phospholipases to release free prostanoids. Metabolizes 2-arachidonoyl
CC       glycerol yielding the glyceryl ester of PGH2, a process that can
CC       contribute to pain response. Generates lipid mediators from n-3 and n-6
CC       polyunsaturated fatty acids (PUFAs) via a lipoxygenase-type mechanism.
CC       Oxygenates PUFAs to hydroperoxy compounds and then reduces them to
CC       corresponding alcohols. Plays a role in the generation of resolution
CC       phase interaction products (resolvins) during both sterile and
CC       infectious inflammation. Metabolizes docosahexaenoate (DHA, C22:6(n-3))
CC       to 17R-HDHA, a precursor of the D-series resolvins (RvDs). As a
CC       component of the biosynthetic pathway of E-series resolvins (RvEs),
CC       converts eicosapentaenoate (EPA, C20:5(n-3)) primarily to 18S-HEPE that
CC       is further metabolized by ALOX5 and LTA4H to generate 18S-RvE1 and 18S-
CC       RvE2. In vascular endothelial cells, converts docosapentaenoate (DPA,
CC       C22:5(n-3)) to 13R-HDPA, a precursor for 13-series resolvins (RvTs)
CC       shown to activate macrophage phagocytosis during bacterial infection.
CC       In activated leukocytes, contributes to oxygenation of
CC       hydroxyeicosatetraenoates (HETE) to diHETES (5,15-diHETE and 5,11-
CC       diHETE). Can also use linoleate (LA, (9Z,12Z)-octadecadienoate,
CC       C18:2(n-6)) as substrate and produce hydroxyoctadecadienoates (HODEs)
CC       in a regio- and stereospecific manner, being (9R)-HODE ((9R)-hydroxy-
CC       (10E,12Z)-octadecadienoate) and (13S)-HODE ((13S)-hydroxy-(9Z,11E)-
CC       octadecadienoate) its major products (By similarity). During
CC       neuroinflammation, plays a role in neuronal secretion of specialized
CC       preresolving mediators (SPMs) 15R-lipoxin A4 that regulates phagocytic
CC       microglia (By similarity). {ECO:0000250|UniProtKB:P35354,
CC       ECO:0000250|UniProtKB:P79208, ECO:0000250|UniProtKB:Q05769}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + AH2 + 2 O2 = A + H2O +
CC         prostaglandin H2; Xref=Rhea:RHEA:23728, ChEBI:CHEBI:13193,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15379, ChEBI:CHEBI:17499,
CC         ChEBI:CHEBI:32395, ChEBI:CHEBI:57405; EC=1.14.99.1;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:23729;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + 2 O2 = prostaglandin G2;
CC         Xref=Rhea:RHEA:42596, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395,
CC         ChEBI:CHEBI:82629; Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42597;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=AH2 + prostaglandin G2 = A + H2O + prostaglandin H2;
CC         Xref=Rhea:RHEA:42600, ChEBI:CHEBI:13193, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:17499, ChEBI:CHEBI:57405, ChEBI:CHEBI:82629;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42601;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + 2 O2 = prostaglandin
CC         G3; Xref=Rhea:RHEA:50444, ChEBI:CHEBI:15379, ChEBI:CHEBI:58562,
CC         ChEBI:CHEBI:133133; Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50445;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=AH2 + prostaglandin G3 = A + H2O + prostaglandin H3;
CC         Xref=Rhea:RHEA:50448, ChEBI:CHEBI:13193, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:17499, ChEBI:CHEBI:133133, ChEBI:CHEBI:133134;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50449;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(8Z,11Z,14Z)-eicosatrienoate + 2 O2 = prostaglandin G1;
CC         Xref=Rhea:RHEA:50424, ChEBI:CHEBI:15379, ChEBI:CHEBI:71589,
CC         ChEBI:CHEBI:133084; Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50425;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=AH2 + prostaglandin G1 = A + H2O + prostaglandin H1;
CC         Xref=Rhea:RHEA:50432, ChEBI:CHEBI:13193, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:17499, ChEBI:CHEBI:90793, ChEBI:CHEBI:133084;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50433;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-
CC         phosphoethanolamine + 2 O2 = 2-(prostaglandin G2)-sn-glycero-3-
CC         phosphoethanolamine; Xref=Rhea:RHEA:54204, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:76091, ChEBI:CHEBI:138098;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:54205;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-(prostaglandin G2)-sn-glycero-3-phosphoethanolamine + AH2 =
CC         2-(prostaglandin H2)-sn-glycero-3-phosphoethanolamine + A + H2O;
CC         Xref=Rhea:RHEA:54208, ChEBI:CHEBI:13193, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:17499, ChEBI:CHEBI:138098, ChEBI:CHEBI:138099;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:54209;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-phosphocholine
CC         + 2 O2 = 2-(prostaglandin G2)-sn-glycero-3-phosphocholine;
CC         Xref=Rhea:RHEA:54212, ChEBI:CHEBI:15379, ChEBI:CHEBI:76079,
CC         ChEBI:CHEBI:138100; Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:54213;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-(prostaglandin G2)-sn-glycero-3-phosphocholine + AH2 = 2-
CC         (prostaglandin H2)-sn-glycero-3-phosphocholine + A + H2O;
CC         Xref=Rhea:RHEA:54216, ChEBI:CHEBI:13193, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:17499, ChEBI:CHEBI:138100, ChEBI:CHEBI:138101;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:54217;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoate + AH2 =
CC         (15S)-hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoate + A + H2O;
CC         Xref=Rhea:RHEA:48856, ChEBI:CHEBI:13193, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:17499, ChEBI:CHEBI:57409, ChEBI:CHEBI:57446;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48857;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-phosphocholine
CC         + AH2 + O2 = 2-[(15S)-hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoyl]-sn-
CC         glycero-3-phosphocholine + A + H2O; Xref=Rhea:RHEA:53684,
CC         ChEBI:CHEBI:13193, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:17499, ChEBI:CHEBI:76079, ChEBI:CHEBI:137584;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53685;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-phosphocholine
CC         + AH2 + O2 = 2-[(15R)-hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoyl]-sn-
CC         glycero-3-phosphocholine + A + H2O; Xref=Rhea:RHEA:53680,
CC         ChEBI:CHEBI:13193, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:17499, ChEBI:CHEBI:76079, ChEBI:CHEBI:137583;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53681;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-phosphocholine
CC         + AH2 + O2 = 2-[(11R)-hydroxy-(5Z,8Z,12E,14Z)-eicosatetraenoyl]-sn-
CC         glycero-3-phosphocholine + A + H2O; Xref=Rhea:RHEA:53676,
CC         ChEBI:CHEBI:13193, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:17499, ChEBI:CHEBI:76079, ChEBI:CHEBI:137582;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53677;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(9Z,12Z)-octadecadienoate + AH2 + O2 = 9-hydroxy-(10E,12Z)-
CC         octadecadienoate + A + H2O; Xref=Rhea:RHEA:50864, ChEBI:CHEBI:13193,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15379, ChEBI:CHEBI:17499,
CC         ChEBI:CHEBI:30245, ChEBI:CHEBI:133820;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50865;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(9Z,12Z)-octadecadienoate + AH2 + O2 = 13-hydroxy-(9Z,11E)-
CC         octadecadienoate + A + H2O; Xref=Rhea:RHEA:50860, ChEBI:CHEBI:13193,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15379, ChEBI:CHEBI:17499,
CC         ChEBI:CHEBI:30245, ChEBI:CHEBI:133819;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50861;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + AH2 + O2 = (15R)-hydroxy-
CC         (5Z,8Z,11Z,13E)-eicosatetraenoate + A + H2O; Xref=Rhea:RHEA:50856,
CC         ChEBI:CHEBI:13193, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:17499, ChEBI:CHEBI:32395, ChEBI:CHEBI:78837;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50857;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + AH2 + O2 = (11R)-hydroxy-
CC         (5Z,8Z,12E,14Z)-eicosatetraenoate + A + H2O; Xref=Rhea:RHEA:50852,
CC         ChEBI:CHEBI:13193, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:17499, ChEBI:CHEBI:32395, ChEBI:CHEBI:78836;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50853;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + AH2 + O2 = (11R)-
CC         hydroxy-(5Z,8Z,12E,14Z,17Z)-eicosapentaenoate + A + H2O;
CC         Xref=Rhea:RHEA:50848, ChEBI:CHEBI:13193, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:17499, ChEBI:CHEBI:58562,
CC         ChEBI:CHEBI:90820; Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50849;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + AH2 + O2 = (18S)-
CC         hydroxy-(5Z,8Z,11Z,14Z,16E)-eicosapentaenoate + A + H2O;
CC         Xref=Rhea:RHEA:50200, ChEBI:CHEBI:13193, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:17499, ChEBI:CHEBI:58562,
CC         ChEBI:CHEBI:132083; Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50201;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + AH2 + O2 = (18R)-
CC         hydroxy-(5Z,8Z,11Z,14Z,16E)-eicosapentaenoate + A + H2O;
CC         Xref=Rhea:RHEA:48836, ChEBI:CHEBI:13193, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:17499, ChEBI:CHEBI:58562,
CC         ChEBI:CHEBI:90818; Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48837;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + AH2 + O2 = (15R)-
CC         hydroxy-(5Z,8Z,11Z,13E,17Z)-eicosapentaenoate + A + H2O;
CC         Xref=Rhea:RHEA:48840, ChEBI:CHEBI:13193, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:17499, ChEBI:CHEBI:58562,
CC         ChEBI:CHEBI:90819; Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48841;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + AH2 + O2 = (15S)-
CC         hydroxy-(5Z,8Z,11Z,13E,17Z)-eicosapentaenoate + A + H2O;
CC         Xref=Rhea:RHEA:50196, ChEBI:CHEBI:13193, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:17499, ChEBI:CHEBI:58562,
CC         ChEBI:CHEBI:132087; Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50197;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(7Z,10Z,13Z,16Z,19Z)-docosapentaenoate + AH2 + O2 = 13R-
CC         hydroxy-(7Z,10Z,14E,16Z,19Z)-docosapentaenoate + A + H2O;
CC         Xref=Rhea:RHEA:48852, ChEBI:CHEBI:13193, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:17499, ChEBI:CHEBI:77224,
CC         ChEBI:CHEBI:90824; Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48853;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate + AH2 + O2 = 13-
CC         hydroxy-(4Z,7Z,10Z,14E,16Z,19Z)-docosahexaenoate + A + H2O;
CC         Xref=Rhea:RHEA:48820, ChEBI:CHEBI:13193, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:17499, ChEBI:CHEBI:77016,
CC         ChEBI:CHEBI:90815; Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48821;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5S)-hydroxy-(6E,8Z,11Z,14Z)-eicosatetraenoate + AH2 + O2 =
CC         (5S,15R)-dihydroxy-(6E,8Z,11Z,13E)-eicosatetraenoate + A + H2O;
CC         Xref=Rhea:RHEA:48812, ChEBI:CHEBI:13193, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:17499, ChEBI:CHEBI:90632,
CC         ChEBI:CHEBI:90812; Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48813;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate + AH2 + O2 = 17R-
CC         hydroxy-(4Z,7Z,10Z,13Z,15E,19Z)-docosahexaenoate + A + H2O;
CC         Xref=Rhea:RHEA:48816, ChEBI:CHEBI:13193, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:17499, ChEBI:CHEBI:77016,
CC         ChEBI:CHEBI:90814; Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48817;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5S)-hydroxy-(6E,8Z,11Z,14Z)-eicosatetraenoate + AH2 + O2 =
CC         (5S,15S)-dihydroxy-(6E,8Z,11Z,13E)-eicosatetraenoate + A + H2O;
CC         Xref=Rhea:RHEA:48808, ChEBI:CHEBI:13193, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:17499, ChEBI:CHEBI:90632,
CC         ChEBI:CHEBI:90813; Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48809;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5S)-hydroxy-(6E,8Z,11Z,14Z)-eicosatetraenoate + AH2 + O2 =
CC         (5S,11R)-dihydroxy-(6E,8Z,12E,14Z)-eicosatetraenoate + A + H2O;
CC         Xref=Rhea:RHEA:48804, ChEBI:CHEBI:13193, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:17499, ChEBI:CHEBI:90632,
CC         ChEBI:CHEBI:90810; Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:48805;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-glycerol + 2 O2 = 2-
CC         glyceryl-prostaglandin G2; Xref=Rhea:RHEA:45288, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:52392, ChEBI:CHEBI:85165;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45289;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-glyceryl-prostaglandin G2 + AH2 = 2-glyceryl-prostaglandin
CC         H2 + A + H2O; Xref=Rhea:RHEA:45292, ChEBI:CHEBI:13193,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:17499, ChEBI:CHEBI:85165,
CC         ChEBI:CHEBI:85166; Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45293;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 = (15R)-hydroperoxy-
CC         (5Z,8Z,11Z,13E)-eicosatetraenoate; Xref=Rhea:RHEA:42284,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:82626;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42285;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 = 11R-hydroperoxy-
CC         (5Z,8Z,12E,14Z)-eicosatetraenoate; Xref=Rhea:RHEA:42280,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:82628;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42281;
CC         Evidence={ECO:0000250|UniProtKB:P35354};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(9Z,12Z)-octadecadienoate + AH2 + O2 = (9R)-hydroxy-(10E,12Z)-
CC         octadecadienoate + A + H2O; Xref=Rhea:RHEA:75447, ChEBI:CHEBI:13193,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15379, ChEBI:CHEBI:17499,
CC         ChEBI:CHEBI:30245, ChEBI:CHEBI:77895;
CC         Evidence={ECO:0000250|UniProtKB:P79208};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:75448;
CC         Evidence={ECO:0000250|UniProtKB:P79208};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(9Z,12Z)-octadecadienoate + AH2 + O2 = (9S)-hydroxy-(10E,12Z)-
CC         octadecadienoate + A + H2O; Xref=Rhea:RHEA:75459, ChEBI:CHEBI:13193,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15379, ChEBI:CHEBI:17499,
CC         ChEBI:CHEBI:30245, ChEBI:CHEBI:77852;
CC         Evidence={ECO:0000250|UniProtKB:P79208};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:75460;
CC         Evidence={ECO:0000250|UniProtKB:P79208};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(9Z,12Z)-octadecadienoate + AH2 + O2 = (13S)-hydroxy-(9Z,11E)-
CC         octadecadienoate + A + H2O; Xref=Rhea:RHEA:75451, ChEBI:CHEBI:13193,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15379, ChEBI:CHEBI:17499,
CC         ChEBI:CHEBI:30245, ChEBI:CHEBI:90850;
CC         Evidence={ECO:0000250|UniProtKB:P79208};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:75452;
CC         Evidence={ECO:0000250|UniProtKB:P79208};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(9Z,12Z)-octadecadienoate + AH2 + O2 = (13R)-hydroxy-(9Z,11E)-
CC         octadecadienoate + A + H2O; Xref=Rhea:RHEA:75455, ChEBI:CHEBI:13193,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15379, ChEBI:CHEBI:17499,
CC         ChEBI:CHEBI:30245, ChEBI:CHEBI:136655;
CC         Evidence={ECO:0000250|UniProtKB:P79208};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:75456;
CC         Evidence={ECO:0000250|UniProtKB:P79208};
CC   -!- COFACTOR:
CC       Name=heme b; Xref=ChEBI:CHEBI:60344;
CC         Evidence={ECO:0000250|UniProtKB:Q05769};
CC       Note=Binds 1 heme b (iron(II)-protoporphyrin IX) group per subunit.
CC       {ECO:0000250|UniProtKB:Q05769};
CC   -!- PATHWAY: Lipid metabolism; prostaglandin biosynthesis.
CC       {ECO:0000250|UniProtKB:P35354}.
CC   -!- SUBUNIT: Homodimer. {ECO:0000250|UniProtKB:Q05769}.
CC   -!- SUBCELLULAR LOCATION: Microsome membrane
CC       {ECO:0000250|UniProtKB:P35354}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:P35354}. Endoplasmic reticulum membrane
CC       {ECO:0000250|UniProtKB:P35354}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:P35354}. Nucleus inner membrane
CC       {ECO:0000250|UniProtKB:P35354}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:P35354}. Nucleus outer membrane
CC       {ECO:0000250|UniProtKB:P35354}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:P35354}. Note=Detected on the lumenal side of
CC       the endoplasmic reticulum and nuclear envelope.
CC       {ECO:0000250|UniProtKB:P35354}.
CC   -!- TISSUE SPECIFICITY: Expressed throughout the forebrain in discrete
CC       populations of neurons and is enriched in the cortex and hippocampus.
CC   -!- INDUCTION: By cytokines and mitogens.
CC   -!- PTM: S-nitrosylation by NOS2 (iNOS) activates enzyme activity. S-
CC       nitrosylation may take place on different Cys residues in addition to
CC       Cys-526. {ECO:0000250|UniProtKB:P35354}.
CC   -!- PTM: Acetylated at Ser-565 by SPHK1. During neuroinflammation,
CC       acetylation by SPHK1 promotes neuronal secretion of specialized
CC       preresolving mediators (SPMs), especially 15-R-lipoxin A4, which
CC       results in an increase of phagocytic microglia.
CC       {ECO:0000250|UniProtKB:Q05769}.
CC   -!- MISCELLANEOUS: The conversion of arachidonate to prostaglandin H2 is a
CC       2 step reaction: a cyclooxygenase (COX) reaction which converts
CC       arachidonate to prostaglandin G2 (PGG2) and a peroxidase reaction in
CC       which PGG2 is reduced to prostaglandin H2 (PGH2). The cyclooxygenase
CC       reaction occurs in a hydrophobic channel in the core of the enzyme. The
CC       peroxidase reaction occurs at a heme-containing active site located
CC       near the protein surface. The nonsteroidal anti-inflammatory drugs
CC       (NSAIDs) binding site corresponds to the cyclooxygenase active site.
CC   -!- MISCELLANEOUS: Conversion of arachidonate to prostaglandin H2 is
CC       mediated by 2 different isozymes: the constitutive PTGS1 and the
CC       inducible PTGS2. PTGS1 is expressed constitutively and generally
CC       produces prostanoids acutely in response to hormonal stimuli to fine-
CC       tune physiological processes requiring instantaneous, continuous
CC       regulation (e.g. hemostasis). PTGS2 is inducible and typically produces
CC       prostanoids that mediate responses to physiological stresses such as
CC       infection and inflammation.
CC   -!- MISCELLANEOUS: PTGS1 and PTGS2 are the targets of nonsteroidal anti-
CC       inflammatory drugs (NSAIDs) including aspirin and ibuprofen. Aspirin is
CC       able to produce an irreversible inactivation of the enzyme through a
CC       serine acetylation. Inhibition of the PGHSs with NSAIDs acutely reduces
CC       inflammation, pain, and fever, and long-term use of these drugs reduces
CC       fatal thrombotic events, as well as the development of colon cancer and
CC       Alzheimer's disease. PTGS2 is the principal isozyme responsible for
CC       production of inflammatory prostaglandins. New generation PTGSs
CC       inhibitors strive to be selective for PTGS2, to avoid side effects such
CC       as gastrointestinal complications and ulceration.
CC   -!- SIMILARITY: Belongs to the prostaglandin G/H synthase family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L25925; AAA16477.1; -; mRNA.
DR   EMBL; U04300; AAA20246.1; -; mRNA.
DR   EMBL; U03389; AAA03466.1; -; mRNA.
DR   EMBL; S67722; AAB29401.1; -; mRNA.
DR   EMBL; AF233596; AAF36986.1; -; mRNA.
DR   PIR; JC2030; JC2030.
DR   RefSeq; NP_058928.3; NM_017232.3.
DR   AlphaFoldDB; P35355; -.
DR   SMR; P35355; -.
DR   BioGRID; 248163; 6.
DR   CORUM; P35355; -.
DR   IntAct; P35355; 1.
DR   STRING; 10116.ENSRNOP00000003567; -.
DR   BindingDB; P35355; -.
DR   ChEMBL; CHEMBL2977; -.
DR   DrugCentral; P35355; -.
DR   PeroxiBase; 3975; RnoPGHS02-A.
DR   GlyCosmos; P35355; 4 sites, No reported glycans.
DR   GlyGen; P35355; 4 sites.
DR   iPTMnet; P35355; -.
DR   PhosphoSitePlus; P35355; -.
DR   jPOST; P35355; -.
DR   PaxDb; 10116-ENSRNOP00000003567; -.
DR   Ensembl; ENSRNOT00000003567.5; ENSRNOP00000003567.2; ENSRNOG00000002525.5.
DR   Ensembl; ENSRNOT00055031581; ENSRNOP00055025514; ENSRNOG00055018563.
DR   GeneID; 29527; -.
DR   KEGG; rno:29527; -.
DR   UCSC; RGD:620349; rat.
DR   AGR; RGD:620349; -.
DR   CTD; 5743; -.
DR   RGD; 620349; Ptgs2.
DR   eggNOG; KOG2408; Eukaryota.
DR   GeneTree; ENSGT00390000010743; -.
DR   HOGENOM; CLU_022428_0_0_1; -.
DR   InParanoid; P35355; -.
DR   OMA; NVHYGYK; -.
DR   OrthoDB; 1086441at2759; -.
DR   PhylomeDB; P35355; -.
DR   TreeFam; TF329675; -.
DR   BRENDA; 1.14.99.1; 5301.
DR   Reactome; R-RNO-197264; Nicotinamide salvaging.
DR   Reactome; R-RNO-2142770; Synthesis of 15-eicosatetraenoic acid derivatives.
DR   Reactome; R-RNO-2162123; Synthesis of Prostaglandins (PG) and Thromboxanes (TX).
DR   Reactome; R-RNO-9018677; Biosynthesis of DHA-derived SPMs.
DR   Reactome; R-RNO-9018679; Biosynthesis of EPA-derived SPMs.
DR   Reactome; R-RNO-9025094; Biosynthesis of DPAn-3 SPMs.
DR   Reactome; R-RNO-9027604; Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives.
DR   UniPathway; UPA00662; -.
DR   PRO; PR:P35355; -.
DR   Proteomes; UP000002494; Chromosome 13.
DR   Bgee; ENSRNOG00000002525; Expressed in Ammon's horn and 16 other cell types or tissues.
DR   GO; GO:0005901; C:caveola; IDA:RGD.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISO:RGD.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043005; C:neuron projection; ISO:RGD.
DR   GO; GO:0005637; C:nuclear inner membrane; ISS:UniProtKB.
DR   GO; GO:0005640; C:nuclear outer membrane; ISS:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:RGD.
DR   GO; GO:0019899; F:enzyme binding; ISO:RGD.
DR   GO; GO:0020037; F:heme binding; ISS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0016702; F:oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen; IDA:RGD.
DR   GO; GO:0004601; F:peroxidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004666; F:prostaglandin-endoperoxide synthase activity; ISS:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:RGD.
DR   GO; GO:0001525; P:angiogenesis; IMP:RGD.
DR   GO; GO:0030282; P:bone mineralization; IMP:MGI.
DR   GO; GO:0050873; P:brown fat cell differentiation; ISO:RGD.
DR   GO; GO:0071318; P:cellular response to ATP; IEP:RGD.
DR   GO; GO:0071498; P:cellular response to fluid shear stress; ISO:RGD.
DR   GO; GO:0034605; P:cellular response to heat; IEP:RGD.
DR   GO; GO:1905375; P:cellular response to homocysteine; IEP:RGD.
DR   GO; GO:0071456; P:cellular response to hypoxia; ISO:RGD.
DR   GO; GO:0071284; P:cellular response to lead ion; IEP:RGD.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:RGD.
DR   GO; GO:0071471; P:cellular response to non-ionic osmotic stress; ISO:RGD.
DR   GO; GO:0071417; P:cellular response to organonitrogen compound; IEP:RGD.
DR   GO; GO:0019371; P:cyclooxygenase pathway; ISS:UniProtKB.
DR   GO; GO:0046697; P:decidualization; IMP:RGD.
DR   GO; GO:0007566; P:embryo implantation; IMP:RGD.
DR   GO; GO:0042633; P:hair cycle; IEP:RGD.
DR   GO; GO:0007612; P:learning; IMP:RGD.
DR   GO; GO:0035633; P:maintenance of blood-brain barrier; IMP:RGD.
DR   GO; GO:0007613; P:memory; IMP:RGD.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISO:RGD.
DR   GO; GO:0051926; P:negative regulation of calcium ion transport; IMP:RGD.
DR   GO; GO:0045786; P:negative regulation of cell cycle; IGI:RGD.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:RGD.
DR   GO; GO:1902219; P:negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress; ISO:RGD.
DR   GO; GO:0045986; P:negative regulation of smooth muscle contraction; IMP:RGD.
DR   GO; GO:0032227; P:negative regulation of synaptic transmission, dopaminergic; IMP:RGD.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:RGD.
DR   GO; GO:0090336; P:positive regulation of brown fat cell differentiation; ISO:RGD.
DR   GO; GO:0090050; P:positive regulation of cell migration involved in sprouting angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:RGD.
DR   GO; GO:0031622; P:positive regulation of fever generation; IDA:BHF-UCL.
DR   GO; GO:0090271; P:positive regulation of fibroblast growth factor production; IMP:BHF-UCL.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; ISO:RGD.
DR   GO; GO:0090362; P:positive regulation of platelet-derived growth factor production; IMP:BHF-UCL.
DR   GO; GO:0031394; P:positive regulation of prostaglandin biosynthetic process; ISO:RGD.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; IMP:RGD.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IMP:RGD.
DR   GO; GO:0045987; P:positive regulation of smooth muscle contraction; IMP:RGD.
DR   GO; GO:0031915; P:positive regulation of synaptic plasticity; IMP:RGD.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; IMP:RGD.
DR   GO; GO:0071636; P:positive regulation of transforming growth factor beta production; IMP:BHF-UCL.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; IMP:BHF-UCL.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IMP:RGD.
DR   GO; GO:0001516; P:prostaglandin biosynthetic process; IMP:RGD.
DR   GO; GO:0032310; P:prostaglandin secretion; ISO:RGD.
DR   GO; GO:0008217; P:regulation of blood pressure; ISS:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell population proliferation; ISO:RGD.
DR   GO; GO:0150077; P:regulation of neuroinflammatory response; ISS:UniProtKB.
DR   GO; GO:1990776; P:response to angiotensin; IEP:RGD.
DR   GO; GO:0034097; P:response to cytokine; IMP:RGD.
DR   GO; GO:0032355; P:response to estradiol; IEP:RGD.
DR   GO; GO:0070542; P:response to fatty acid; IEP:RGD.
DR   GO; GO:0009750; P:response to fructose; IEP:RGD.
DR   GO; GO:0051384; P:response to glucocorticoid; IEP:RGD.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IMP:RGD.
DR   GO; GO:0010042; P:response to manganese ion; IEP:RGD.
DR   GO; GO:0009624; P:response to nematode; ISO:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0006979; P:response to oxidative stress; IEA:InterPro.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IEP:RGD.
DR   GO; GO:0033280; P:response to vitamin D; IEP:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEP:RGD.
DR   CDD; cd00054; EGF_CA; 1.
DR   CDD; cd09816; prostaglandin_endoperoxide_synthase; 1.
DR   Gene3D; 1.10.640.10; Haem peroxidase domain superfamily, animal type; 1.
DR   Gene3D; 2.10.25.10; Laminin; 1.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR019791; Haem_peroxidase_animal.
DR   InterPro; IPR010255; Haem_peroxidase_sf.
DR   InterPro; IPR037120; Haem_peroxidase_sf_animal.
DR   InterPro; IPR050783; Oxylipin_biosynth_metab.
DR   PANTHER; PTHR11903; PROSTAGLANDIN G/H SYNTHASE; 1.
DR   PANTHER; PTHR11903:SF8; PROSTAGLANDIN G_H SYNTHASE 2; 1.
DR   Pfam; PF03098; An_peroxidase; 2.
DR   Pfam; PF00008; EGF; 1.
DR   PRINTS; PR00457; ANPEROXIDASE.
DR   SUPFAM; SSF57196; EGF/Laminin; 1.
DR   SUPFAM; SSF48113; Heme-dependent peroxidases; 1.
DR   PROSITE; PS50026; EGF_3; 1.
DR   PROSITE; PS50292; PEROXIDASE_3; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Dioxygenase; Direct protein sequencing; Disulfide bond;
KW   Endoplasmic reticulum; Fatty acid biosynthesis; Fatty acid metabolism;
KW   Glycoprotein; Heme; Iron; Lipid biosynthesis; Lipid metabolism; Membrane;
KW   Metal-binding; Microsome; Nucleus; Oxidoreductase; Peroxidase;
KW   Prostaglandin biosynthesis; Prostaglandin metabolism; Reference proteome;
KW   S-nitrosylation; Signal.
FT   SIGNAL          1..17
FT                   /evidence="ECO:0000269|PubMed:1556140"
FT   CHAIN           18..604
FT                   /note="Prostaglandin G/H synthase 2"
FT                   /id="PRO_0000023879"
FT   DOMAIN          18..55
FT                   /note="EGF-like"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   ACT_SITE        193
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00298"
FT   ACT_SITE        371
FT                   /note="For cyclooxygenase activity"
FT                   /evidence="ECO:0000250|UniProtKB:Q05769"
FT   BINDING         106
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:Q05769"
FT   BINDING         341
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:Q05769"
FT   BINDING         374
FT                   /ligand="heme b"
FT                   /ligand_id="ChEBI:CHEBI:60344"
FT                   /ligand_part="Fe"
FT                   /ligand_part_id="ChEBI:CHEBI:18248"
FT                   /note="axial binding residue"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00298"
FT   SITE            516
FT                   /note="Aspirin-acetylated serine"
FT                   /evidence="ECO:0000250|UniProtKB:P35354"
FT   MOD_RES         526
FT                   /note="S-nitrosocysteine"
FT                   /evidence="ECO:0000250|UniProtKB:P35354"
FT   MOD_RES         565
FT                   /note="O-acetylserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q05769"
FT   CARBOHYD        53
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        130
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        396
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        580
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        21..32
FT                   /evidence="ECO:0000250|UniProtKB:Q05769"
FT   DISULFID        22..145
FT                   /evidence="ECO:0000250|UniProtKB:Q05769"
FT   DISULFID        26..42
FT                   /evidence="ECO:0000250|UniProtKB:Q05769"
FT   DISULFID        44..54
FT                   /evidence="ECO:0000250|UniProtKB:Q05769"
FT   DISULFID        555..561
FT                   /evidence="ECO:0000250|UniProtKB:Q05769"
FT   CONFLICT        11..13
FT                   /note="ALA -> CPG (in Ref. 4 and 5)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        58
FT                   /note="E -> R (in Ref. 4 and 5)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        66
FT                   /note="L -> P (in Ref. 4 and 5)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        96..98
FT                   /note="NSI -> IQS (in Ref. 4 and 5)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        339
FT                   /note="S -> R (in Ref. 4 and 5)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        344
FT                   /note="K -> Q (in Ref. 4 and 5)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        350
FT                   /note="E -> D (in Ref. 4 and 5)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        368
FT                   /note="N -> K (in Ref. 4 and 5)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        573
FT                   /note="P -> A (in Ref. 4 and 5)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   604 AA;  69164 MW;  98E418825D98FF0C CRC64;
     MLFRAVLLCA ALALSHAANP CCSNPCQNRG ECMSIGFDQY KCDCTRTGFY GENCTTPEFL
     TRIKLLLKPT PNTVHYILTH FKGVWNIVNN IPFLRNSIMR YVLTSRSHLI DSPPTYNVHY
     GYKSWEAFSN LSYYTRALPP VADDCPTPMG VKGNKELPDS KEVLEKVLLR REFIPDPQGT
     NMMFAFFAQH FTHQFFKTDQ KRGPGFTRGL GHGVDLNHVY GETLDRQHKL RLFQDGKLKY
     QVIGGEVYPP TVKDTQVDMI YPPHVPEHLR FAVGQEVFGL VPGLMMYATI WLREHNRVCD
     ILKQEHPEWD DERLFQTSRL ILIGETIKIV IEDYVQHLSG YHFKLKFDPE LLFNQQFQYQ
     NRIASEFNTL YHWHPLLPDT FNIEDQEYTF KQFLYNNSIL LEHGLAHFVE SFTRQIAGRV
     AGGRNVPIAV QAVAKASIDQ SREMKYQSLN EYRKRFSLKP YTSFEELTGE KEMAAELKAL
     YHDIDAMELY PALLVEKPRP DAIFGETMVE LGAPFSLKGL MGNPICSPQY WKPSTFGGEV
     GFRIINTASI QSLICNNVKG CPFASFNVQD PQPTKTATIN ASASHSRLDD INPTVLIKRR
     STEL
//
